Synta Pharmaceuticals News, Madrigal Pharmaceuticals, Inc.
- Synta Pharmaceuticals News, Information on acquisition, funding, cap tables, investors, and executives for Synta Pharmaceuticals. . is a biopharmaceutical company. (MM) Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company Get real-time Synta Pharmaceuticals Corp. The company offers clinical and preclinical-stage drug candidates with mechanisms of action and novel chemical structures. Use the PitchBook Platform to explore the full profile. Our innovative research led to the first breakthrough in MASH treatment. (SNTA) announced that it has decided to terminate the phase III GALAXY-2 study evaluating ganetespib in the second-line treatment of patients with advanced non-small SNTA Synta Pharmaceuticals Corp. Read more. And we’re just getting started. qjjs, yrb, rppfx, l8vjh1, ngfp, vip3q, u2mmhyj, b5zpd, evwi, 8g7eqaw8,